Peptide News Digest

#Redefine-4

2 stories

Industry · View digest

Novo Nordisk (NYSE: NVO) Shares Fell Approximately 6% Thursday August 13, 2026 on Broker Downgrade Citing Continued Franchise-Gap Pressure From Eli Lilly's (NYSE: LLY) Tirzepatide Franchise and the CagriSema Head-to-Head Miss Against Tirzepatide (23.0% Versus 25.5% Weight Loss at 84 Weeks in the REDEFINE 4 Head-to-Head Phase 3 Trial); The August 4 H1 2026 Earnings Release Raised Full-Year 2026 Sales Guidance to Down 3% From Prior Down 8% Midpoint but the Broader Investor Narrative Continues to Focus on Novo's Ability to Defend GLP-1 Franchise Economics Against Eli Lilly's Q2 2026 $23 Billion Revenue Blowout (+48% YoY), Foundayo (Orforglipron) $98 Million First Commercial Quarter, and Retatrutide's 28.7% Phase 3 TRIUMPH-4 Weight Loss Result

Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday August 13, 2026 on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise (Mounjaro + Zepbound) and the CagriSema head-to-head miss against tirzepatide. Specifics: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination) reached 23.0% weight loss at 84 weeks versus tirzepatide 15 mg's 25.5% in the REDEFINE 4 head-to-head Phase 3 trial published in early August 2026. The August 4 H1 2026 earnings release raised full-year 2026 sales guidance to down 3% from a prior down 8% midpoint at constant exchange rates. The broader investor narrative continues to focus on Novo's ability to defend GLP-1 franchise economics against Eli Lilly's Q2 2026 $23 billion revenue blowout (+48% year-over-year), Foundayo (orforglipron) $98 million first commercial quarter, and retatrutide's 28.7% Phase 3 TRIUMPH-4 weight loss result at 68 weeks. Analyst attention now shifts to Novo's Wegovy 7.2 mg higher-dose FDA review, the amycretin oral amylin monotherapy Phase 1b program (roughly 22% weight loss at Week 36), and next-generation candidates in Novo's pipeline. Investors are also watching the CagriSema FDA decision expected late 2026 and whether the label expansion strategy can offset the competitive pressure.

Clinical Trials · View digest

Novo Nordisk REDEFINE 4 Head-to-Head 84-Week Phase 3 Trial Detail: CagriSema (Cagrilintide 2.4 mg + Semaglutide 2.4 mg Fixed-Dose Combination) Versus Tirzepatide 15 mg in 809 Randomized Adults With Obesity and One or More Comorbidities With Mean Baseline Body Weight of 114.2 kg Documented 23.0% Weight Loss on CagriSema Versus 25.5% on Tirzepatide (Treatment-Policy Estimand) and 20.2% Versus 23.6% (Treatment-Regimen Estimand), Missing the Primary Non-Inferiority Endpoint; CagriSema Safety Profile Was Generally Well-Tolerated; The Trial Result Complicates the Novo Commercial Positioning of CagriSema as Its Tirzepatide-Beating Response Even as the FDA Decision on the Obesity Indication (Filed December 18, 2025 Based on REDEFINE 1 and REDEFINE 2 Pivotal Data) Remains Expected Late 2026

Novo Nordisk released detailed data from the REDEFINE 4 head-to-head 84-week Phase 3 trial of CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose combination) versus tirzepatide 15 mg. Trial design: 809 randomized adults with obesity and one or more comorbidities with mean baseline body weight of 114.2 kg, both drugs administered once weekly subcutaneously over 84 weeks. Primary endpoint results: CagriSema 23.0% weight loss versus tirzepatide 25.5% (treatment-policy estimand); CagriSema 20.2% versus tirzepatide 23.6% (treatment-regimen estimand). The trial missed the primary non-inferiority endpoint on weight loss for CagriSema compared to tirzepatide at 84 weeks. CagriSema safety profile was generally well-tolerated. The trial result complicates the Novo commercial positioning of CagriSema as its tirzepatide-beating differentiated response, though the FDA decision on the CagriSema obesity indication remains expected late 2026 based on the REDEFINE 1 and REDEFINE 2 pivotal trials submitted December 18, 2025. The head-to-head result adds to the widening Lilly-Novo franchise gap: Lilly Q2 2026 Mounjaro + Zepbound reached $14.9 billion in the quarter, while Novo H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion).